BR112013031759A2 - crystalline form of indazolyl amide derivatives for the treatment of glucocorticoid receptor-mediated disorders - Google Patents

crystalline form of indazolyl amide derivatives for the treatment of glucocorticoid receptor-mediated disorders

Info

Publication number
BR112013031759A2
BR112013031759A2 BR112013031759A BR112013031759A BR112013031759A2 BR 112013031759 A2 BR112013031759 A2 BR 112013031759A2 BR 112013031759 A BR112013031759 A BR 112013031759A BR 112013031759 A BR112013031759 A BR 112013031759A BR 112013031759 A2 BR112013031759 A2 BR 112013031759A2
Authority
BR
Brazil
Prior art keywords
treatment
indazolyl
crystalline form
glucocorticoid receptor
amide derivatives
Prior art date
Application number
BR112013031759A
Other languages
Portuguese (pt)
Inventor
Helena Ingemo Andersson
Kelly Yvonne Conway
Michael John Quayle
Original Assignee
Astrazeneca Ab
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Bayer Ip Gmbh filed Critical Astrazeneca Ab
Publication of BR112013031759A2 publication Critical patent/BR112013031759A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides". a presente invenção refere-se a formas cristalinas de 2,2,2-trifluor-n-[(1r,2s)-1-[1-(4-fluorfenil)indazol-5-il]óxi-1-(3-metoxifenil)propan-2-il]acetamida, a processos para obtenção das mesmas, a intermediários farmacêuticos usados na produção da mesma, a composições farmacêuticas contendo os mesmos, e ao uso das mesmas em tratamento médico.Patent Summary: "Crystalline form of indazolyl amide derivatives for the treatment of glucocorticoid receptor-mediated disorders". The present invention relates to crystalline forms of 2,2,2-trifluor-n - [(1r, 2s) -1- [1- (4-fluorophenyl) indazol-5-yl] oxy-1- (3- methoxyphenyl) propan-2-yl] acetamide, to processes for obtaining them, to pharmaceutical intermediates used in the production thereof, to pharmaceutical compositions containing them, and to their use in medical treatment.

BR112013031759A 2011-06-29 2012-06-27 crystalline form of indazolyl amide derivatives for the treatment of glucocorticoid receptor-mediated disorders BR112013031759A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
BR112013031759A2 true BR112013031759A2 (en) 2016-12-13

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031759A BR112013031759A2 (en) 2011-06-29 2012-06-27 crystalline form of indazolyl amide derivatives for the treatment of glucocorticoid receptor-mediated disorders

Country Status (16)

Country Link
EP (1) EP2726464A1 (en)
JP (1) JP2014527955A (en)
KR (1) KR20140036230A (en)
CN (1) CN103814015A (en)
AR (1) AR086818A1 (en)
AU (1) AU2012277514A1 (en)
BR (1) BR112013031759A2 (en)
CA (1) CA2839398A1 (en)
IN (1) IN2014MN00023A (en)
MX (1) MX2013014566A (en)
RU (1) RU2013153466A (en)
SG (1) SG195309A1 (en)
TW (1) TW201305115A (en)
UY (1) UY34170A (en)
WO (1) WO2013001294A1 (en)
ZA (1) ZA201309480B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (en) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 Preparation method of (S) -2-chloro-1- (6-fluoro-1-chroman-2-yl) -ethanol
EP4253396A4 (en) * 2020-11-27 2024-09-11 Mirailab Bioscience Inc High-purity beta-nicotinamide mononucleotide (nmn) and method for producing same
KR102571432B1 (en) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 Composition for treating cancer containing indazolyl ester and amide derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (en) 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
NZ605149A (en) 2010-07-21 2014-08-29 Astrazeneca Ab Inhaler
RU2013104637A (en) 2010-07-21 2014-08-27 Астразенека Аб INHALER

Also Published As

Publication number Publication date
TW201305115A (en) 2013-02-01
UY34170A (en) 2013-01-31
ZA201309480B (en) 2015-10-28
AR086818A1 (en) 2014-01-22
MX2013014566A (en) 2014-09-25
JP2014527955A (en) 2014-10-23
CA2839398A1 (en) 2013-01-03
WO2013001294A1 (en) 2013-01-03
CN103814015A (en) 2014-05-21
AU2012277514A1 (en) 2014-01-09
KR20140036230A (en) 2014-03-25
RU2013153466A (en) 2015-08-10
IN2014MN00023A (en) 2015-06-12
EP2726464A1 (en) 2014-05-07
SG195309A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
ECSP13012770A (en) CRYSTAL FORMS OF 5-CHLORINE-N2- (2-ISOPROPOXI-5-METHYL-4-PIPERIDIN-4-IL-PHENYL) -N4- [2- (PROPAN-2-SULPHONYL) -PENYL] -PIRIMIDIN-2,4 -DIAMINE
EA201490864A1 (en) DERIVATIVES (4-PHENYLIMIDAZOL-2-IL) ETYLAMINE AS SODIUM CHANNEL MODULATORS
CR20150114A (en) COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
CL2013003816A1 (en) Compounds derived from carboxamide and urea comprising aromatic substituted pyrazole, vanilloid receptor binders; pharmaceutical composition that includes them; and its use in the treatment and / or prophylaxis of pain, migraine, parkinson's disease, gastrointestinal disorders, osteoporosis, among other diseases.
BR112014016165A2 (en) Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
BR112015018168A2 (en) soft rock inhibitors
NI201500142A (en) 3-ACETYLAMINO-1 (PHENYL-HETEROARIL-AMINOCARBONIL OR PHENYL-HETEROARYL-CARBONYLAMINE) DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
BR112014014452A2 (en) pyrazolpyridine derivatives, their preparation process and their therapeutic use
CL2012002540A1 (en) Agomelatine Hydrochloride Hydrate; crystalline form; Preparation method; pharmaceutical composition; and its use for the treatment of sleep disorders, stress, anxiety, major depression, cardiovascular diseases, among others.
DOP2013000314A (en) TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
EA201100921A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION IN THE TREATMENT OF MATERIAL EXCHANGE DISORDERS
BR112014002674A2 (en) Substituted 3- (biphenyl-3-yl) -4-hydroxy-8-methoxy-1-azaspiro [4.5] dec-3-en-2-ones
BR112014011333B1 (en) compound, pharmaceutical composition and use of the formula compound
BR112014001908A2 (en) substituted heterocyclic aza derivatives
CL2009000464A1 (en) Compounds derived from 3- (n- (azetidin-3-yl) methanesulfonylamino) benzamide act at cannabinoid receptors cb1; procedure to prepare them; Pharmaceutical composition and its use to treat or prevent psychiatric disorders, cognitive disorders, neurodegenerative diseases, metabolism disorders, pain.
BR112014004447A2 (en) biphenylcarboxamides as rock kinase inhibitors
BR112015011898A2 (en) chidamide crystal form a, method for preparing chidamide crystal form a, use of chidamide crystal form a, chidamide crystal form b, method for preparing chidamide crystal form b, use of chidamide crystal form b and pharmaceutical formulation for the treatment of diseases related to cell differentiation and proliferation
BR112013031759A2 (en) crystalline form of indazolyl amide derivatives for the treatment of glucocorticoid receptor-mediated disorders
CL2009000637A1 (en) Substituted sulfonamide derivative compounds, b1r antagonist; pharmaceutical composition comprising them; process of preparation of the compounds, and use in the treatment of pain caused by inflammation, acute, neuropathic, visceral pain, also in diabetes, migraine, among others.
CL2015000580A1 (en) Compounds derived from pyrazole carboxamide, taar modulators; pharmaceutical composition; process to obtain them; and its use for the therapeutic or prophylactic treatment of depression, anxiety disorders, attention deficit hyperactivity disorder, psychotic disorders, schizophrenia and parkinson, among others.
CL2011001829A1 (en) 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound.
CL2008001325A1 (en) Compounds derived from pyrazole-pyridinone; preparation process of said compounds; pharmaceutical composition that includes them; and its use to treat inflammation, paget disease, osteoarthritis, Alzheimer's, among other diseases.
BR112013029416A2 (en) substituted indole derivatives for the treatment of immune disorders
PH12015501407A1 (en) Topical opthalmological pharmaceutical composition containing regorafenib
BR112015007991A2 (en) ethinyl derivatives as modulators of mglur5 receptor activity

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]